Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
SLC6A3 encodes a dopamine transporter which is a member of the sodium- and chloride-dependent neurotransmitter transporter family. Additionally we are shipping SLC6A3 Kits (47) and SLC6A3 Proteins (6) and many more products for this protein.
Showing 10 out of 108 products:
Mouse (Murine) Monoclonal SLC6A3 Primary Antibody for ICC, IF - ABIN1169684
Cremona, Matthies, Pau, Bowton, Speed, Lute, Anderson, Sen, Robertson, Vaughan, Rothman, Galli, Javitch, Yamamoto: Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT. in Nature neuroscience 2011
Show all 3 references for ABIN1169684
Human Polyclonal SLC6A3 Primary Antibody for EIA, WB - ABIN954827
Mazei-Robison, Bowton, Holy, Schmudermaier, Freissmuth, Sitte, Galli, Blakely: Anomalous dopamine release associated with a human dopamine transporter coding variant. in The Journal of neuroscience : the official journal of the Society for Neuroscience 2008
Human Polyclonal SLC6A3 Primary Antibody for IF (cc) - ABIN733373
Ni, Hu, Ren, Luo, Li, Wan, Su: Self-assembling peptide nanofiber scaffolds enhance dopaminergic differentiation of mouse pluripotent stem cells in 3-dimensional culture. in PLoS ONE 2013
Human Polyclonal SLC6A3 Primary Antibody for IHC (fro), WB - ABIN372614
Kish, Kalasinsky, Derkach, Schmunk, Guttman, Ang, Adams, Furukawa, Haycock: Striatal dopaminergic and serotonergic markers in human heroin users. in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2001
DNA of the impulsive but not the calm subjects was methylated at one DAT SNP.
nitrative damage accumulates in midbrain neurons with age; The capacity of a dopamine neuron to accumulate more cytosolic DA, as inferred from DA transporter expression, is related to accumulation of nitrative damage
Endogenous dopamine actions in C. elegans are tightly regulated by synaptic DAT-1.
loss of UNC-64/DAT-1 interactions leads to enhanced synaptic dopamine release
Data suggest that environment pollutants methylmercury and 1-methyl-4-phenylpyridinium decrease release of dopamine from dopaminergic neurons; this mechanism involves down-regulation of expression of Slc6a3.
This study show that Dopamine transporter is enriched in filopodia and induces filopodia formation.
The sigma-1R deficiency through suppressing NR2B (show GRIN2B Antibodies) function and DAT expression can reduce MPTP (show PTPN2 Antibodies)-induced death of dopaminergic neurons and parkinsonism.
DAT gene knockout in mice results dendritic spine loss in pyramidal neurons in the CA1 (show CA1 Antibodies) field of the hippocampus.
Results show that moderate increases in DAT function cause spontaneous dopaminergic cell loss, oxidative stress and fine motor impairment that is reversed by l-DOPA treatment
Chronic and acute reductions of DAT functioning in mice impaired decision-making.
These results demonstrate that the presence of the N-terminal tag leads to impaired DAT protein expression in vivo due in part to improper trafficking of the tagged transporter.
studies demonstrate an in vivo functional impact of the DAT Val559 variant, providing support for the ability of DAT dysfunction to impact risk for mental illness.
The data of this study imply that individual differences in DAT expression (either genetically or pharmacologically induced) may affect susceptibility to addiction of different types of psychostimulants.
findings support the idea that altered DAT and VMAT2 (show Slc18a2 Antibodies) expression affect age-related changes in dopaminergic function.
DAT-mediated dopamine uptake plays a role in the absorption and distribution of dopamine following intranasal administration
the 3'-UTR (show UTS2R Antibodies) VNTR polymorphism is significantly associated with smoking cessation, and smokers with one or more 9-repeat alleles have a 17% higher probability of smoking cessation than smokers carrying no such allele. [meta-analysis]
high SLC6A3 expression in Clear cell renal cell carcinoma (show MOK Antibodies) tissue was correlated with a shorter period of recurrence-free survival following surgery.
Children without the haplotypes associated with the reduced SLC6A3 gene expression and thus lower dopamine functioning appeared to demonstrate altered levels of effortful control as a function of maternal parenting quality.
Computational study providse novel insights into the role of collective dynamics in functionally relevant state-to-state transitions in DAT, at a level of atomistic detail
Higher levels of maternal depressive symptoms predicted reduced cortisol flexibility across challenges for infants with at least one A1 allele of DRD2 (show DRD2 Antibodies) and infants with the 10/10 genotype of SLC6A3
3'-UTR (show UTS2R Antibodies) variable number tandem repeat associated with post-traumatic stress disorder [meta-analysis]
The NET and DAT N Termini Are Critical for Internalization and Postendocytic Sorting.
the putative involvement of DAT1 and DRD4 (show DRD4 Antibodies) genes in the aetiology of Attention-deficit hyperactivity disorder with a main role in modulation of key dimensions of the disorder
we did not find any significant associations of COMT (show COMT Antibodies) or SLC6A3 with inhibitory performance or impulsivity
This study reveals that a common genetic variant in DAT1, previously linked with the clinical stages of dementia in humans, and with increased DAT expression in vitro, is associated with several brain-related health factors, including diagnostic, cognitive, and anatomical indices of neurodegeneration, providing new insight into the pathogenesis of Alzheimer's disease
This gene encodes a dopamine transporter which is a member of the sodium- and chloride-dependent neurotransmitter transporter family. The 3' UTR of this gene contains a 40 bp tandem repeat, referred to as a variable number tandem repeat or VNTR, which can be present in 3 to 11 copies. Variation in the number of repeats is associated with idiopathic epilepsy, attention-deficit hyperactivity disorder, dependence on alcohol and cocaine, susceptibility to Parkinson disease and protection against nicotine dependence.
dopamine transporter variant II
, sodium-dependent dopamine transporter
, solute carrier family 6 (neurotransmitter transporter, dopamine), member 3
, sodium-dependent dopamine transporter-like
, DA transporter
, dopamine transporter 1
, solute carrier family 6 member 3
, solute carrier family 6, member 3